This may reflect more intensive familial (germline) testing for BRCA1/2 mutations in ovarian and breast cancer30 and consequently earlier diagnosis and treatment with fewer cases of progression to metastatic cancer as a result. The gene discussed is BRCA1; the disease is metastatic malignant neoplasm.